BridgeBio gets funding for drug launch; United buys into cell therapy

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

By Delilah Alvarado • July 1, 2026

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

By Kristin Jensen • July 1, 2026

Theravance, after clinical setbacks, agrees to $929M buyout

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

By Jonathan Gardner • June 29, 2026

Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

By Gwendolyn Wu • June 25, 2026

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.

By Ben Fidler • June 22, 2026

cAMPfield lands $180M to build gut disease drug

The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.

By Jonathan Gardner • June 18, 2026

Biogen adds more immune drugs in $1B buyout of secretive startup RayThera

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues. 

By Kristin Jensen • June 18, 2026

Jazz zeroes in on next-gen T cell engagers with AbCellera deal

The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.

By Kristin Jensen • June 17, 2026

Lilly buys non-opioid pain drugmaker 4E

It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.

By Gwendolyn Wu • June 16, 2026

Summit pulls $500M share sale a day after announcing it

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

By Jonathan Gardner • June 11, 2026

GSK boosts cancer pipeline with $11B Nuvalent buyout

The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

By Jonathan Gardner • June 9, 2026

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

By Ben Fidler • June 8, 2026

Incyte to buy blood disorder drug in possibly $2B deal

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

By Jacob Bell • June 8, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

By Kristin Jensen • June 4, 2026

Lilly, Ascidian link up in RNA exon editing pact

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

By Gwendolyn Wu • June 3, 2026

Servier buys into muscular dystrophy with potentially $2.7B deal

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.

By Jacob Bell • June 1, 2026

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

By Ben Fidler • May 29, 2026

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

By Delilah Alvarado • May 26, 2026

Lilly snaps up Engage to advance non-viral genetic medicines

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

By Delilah Alvarado • May 20, 2026

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.

By Jacob Bell • May 19, 2026

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

By Delilah Alvarado • May 12, 2026

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts. 

By Ben Fidler • May 12, 2026

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

By Delilah Alvarado • May 11, 2026

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

By Kelly Bilodeau • May 8, 2026

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

By Gwendolyn Wu • May 7, 2026